• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆碱能活性与左旋多巴诱发的异动症:一项多示踪剂分子成像研究。

Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study.

作者信息

Brumberg Joachim, Küsters Sebastian, Al-Momani Ehab, Marotta Giorgio, Cosgrove Kelly P, van Dyck Christopher H, Herrmann Ken, Homola György A, Pezzoli Gianni, Buck Andreas K, Volkmann Jens, Samnick Samuel, Isaias Ioannis U

机构信息

Department of Nuclear Medicine University Hospital Würzburg and Julius-Maximilians-University Würzburg Germany.

Department of Neurology University Hospital Würzburg and Julius-Maximilians-University Würzburg Germany.

出版信息

Ann Clin Transl Neurol. 2017 Aug 11;4(9):632-639. doi: 10.1002/acn3.438. eCollection 2017 Sep.

DOI:10.1002/acn3.438
PMID:28904985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5590520/
Abstract

OBJECTIVE

To investigate the association between levodopa-induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease.

METHODS

This study included 13 Parkinson's disease patients with peak-of-dose levodopa-induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5-[I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine single-photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [I]N--fluoropropyl-2-carbomethoxy-3-(4-iodophenyl)nortropane single-photon emission computed tomography, to measure dopamine reuptake transporter density and 2-[F]fluoro-2-deoxyglucose positron emission tomography to assess regional cerebral metabolic activity. Striatal binding potentials, uptake values at basal ganglia structures, and correlations with clinical variables were analyzed.

RESULTS

Density of nicotinic acetylcholine receptors in the caudate nucleus of dyskinetic subjects was similar to that of healthy controls and significantly higher to that of nondyskinetic patients, in particular, contralaterally to the clinically most affected side.

INTERPRETATION

Our findings support the hypothesis that the expression of dyskinesia may be related to cholinergic neuronal excitability in a dopaminergic-depleted striatum. Cholinergic signaling would play a role in maintaining striatal dopaminergic responsiveness, possibly defining disease phenotype and progression.

摘要

目的

研究帕金森病患者左旋多巴诱导的运动障碍与纹状体胆碱能活性之间的关联。

方法

本研究纳入了13例出现剂量峰值左旋多巴诱导运动障碍的帕金森病患者、12例无运动障碍患者以及12名健康对照者。参与者接受了5-[I]碘-3-[2(S)-2-氮杂环丁烷基甲氧基]吡啶单光子发射计算机断层扫描(烟碱型乙酰胆碱受体的标志物)、[I]N-氟丙基-2-甲氧基羰基-3-(4-碘苯基)去甲托烷单光子发射计算机断层扫描以测量多巴胺再摄取转运体密度,以及2-[F]氟-2-脱氧葡萄糖正电子发射断层扫描以评估局部脑代谢活性。分析了纹状体结合潜能、基底节结构的摄取值以及与临床变量的相关性。

结果

运动障碍患者尾状核中烟碱型乙酰胆碱受体的密度与健康对照者相似,且显著高于无运动障碍患者,尤其是在临床受累最严重一侧的对侧。

解读

我们的研究结果支持这样的假说,即运动障碍的表达可能与多巴胺能耗竭的纹状体中的胆碱能神经元兴奋性有关。胆碱能信号传导可能在维持纹状体多巴胺能反应性中发挥作用,这可能决定疾病表型和进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e00d/5590520/1049f27d7edd/ACN3-4-632-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e00d/5590520/1049f27d7edd/ACN3-4-632-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e00d/5590520/1049f27d7edd/ACN3-4-632-g001.jpg

相似文献

1
Cholinergic activity and levodopa-induced dyskinesia: a multitracer molecular imaging study.胆碱能活性与左旋多巴诱发的异动症:一项多示踪剂分子成像研究。
Ann Clin Transl Neurol. 2017 Aug 11;4(9):632-639. doi: 10.1002/acn3.438. eCollection 2017 Sep.
2
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.帕金森病伴运动障碍患者左旋多巴的皮质反应。
Eur J Neurosci. 2018 Sep;48(6):2362-2373. doi: 10.1111/ejn.14114. Epub 2018 Sep 3.
3
Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease.壳核5-羟色胺能神经支配:监测帕金森病的运动障碍风险
Neurology. 2015 Sep 8;85(10):853-60. doi: 10.1212/WNL.0000000000001909. Epub 2015 Aug 7.
4
Neuroimaging of dyskinesia.运动障碍的神经影像学检查。
Ann Neurol. 2000 Apr;47(4 Suppl 1):S154-8; discussion S158-9.
5
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.特发性快速眼动睡眠行为障碍患者黑质纹状体功能的连续多巴胺转运体成像:一项前瞻性研究。
Lancet Neurol. 2011 Sep;10(9):797-805. doi: 10.1016/S1474-4422(11)70152-1. Epub 2011 Jul 28.
6
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.健康对照者及早期未用药帕金森病患者的碘-123-N-ω-氟丙基-2β-甲氧基羰基-3β-(4-碘苯基)托烷单光子发射计算机断层扫描
J Nucl Med. 1998 Jul;39(7):1143-8.
7
An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.左旋多巴诱导运动障碍发病机制的放射自显影研究:帕金森病大鼠模型中左旋多巴对多巴胺转运体的调节。
Neurodegener Dis. 2012;9(1):11-7. doi: 10.1159/000328816. Epub 2011 Aug 26.
8
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.脑血管疾病患者多巴胺转运体的123I-FP-CIT单光子发射计算机断层扫描成像及血管性帕金森综合征的临床诊断
J Nucl Med. 2004 Oct;45(10):1688-93.
9
One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.帕金森病中使用[123I]FPCIT单光子发射计算机断层扫描(SPECT)对黑质纹状体多巴胺能通路进行成像的一日方案。
J Nucl Med. 1999 May;40(5):753-61.
10
DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.DAT 成像与 LRRK2 R1441G 帕金森病遗传风险亲属的临床生物标志物。
Mov Disord. 2016 Mar;31(3):335-43. doi: 10.1002/mds.26478. Epub 2015 Dec 21.

引用本文的文献

1
Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.正电子发射断层扫描成像在帕金森病突触功能障碍中的应用。
Neurosci Bull. 2024 Jun;40(6):743-758. doi: 10.1007/s12264-024-01188-0. Epub 2024 Mar 14.
2
Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.多巴胺转运体显像:一个潜在生物标志物的现状综述。
Int J Mol Sci. 2021 Oct 18;22(20):11234. doi: 10.3390/ijms222011234.
3
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia-Literature Review.

本文引用的文献

1
Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.帕金森病中5-羟色胺与多巴胺转运体比率:与运动障碍的相关性。
Neurology. 2016 Mar 22;86(12):1152-8. doi: 10.1212/WNL.0000000000002494. Epub 2016 Feb 26.
2
Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease.壳核5-羟色胺能神经支配:监测帕金森病的运动障碍风险
Neurology. 2015 Sep 8;85(10):853-60. doi: 10.1212/WNL.0000000000001909. Epub 2015 Aug 7.
3
Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection.
左旋多巴诱发异动症的背景、病理生理学及治疗的当前知识——文献综述
J Clin Med. 2021 Sep 25;10(19):4377. doi: 10.3390/jcm10194377.
4
Attentional dysfunction and the punding spectrum in Parkinson's disease.注意功能障碍与帕金森病的“刻板行为”谱。
Parkinsonism Relat Disord. 2021 Mar;84:23-28. doi: 10.1016/j.parkreldis.2021.01.019. Epub 2021 Jan 30.
5
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain.正电子发射断层扫描成像估计活体人脑内乙酰胆碱浓度的区域性变化。
Cereb Cortex. 2021 May 10;31(6):2787-2798. doi: 10.1093/cercor/bhaa387.
6
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?帕金森病的肌张力障碍和左旋多巴诱导的运动障碍:两者之间是否存在关联?
Neurobiol Dis. 2019 Dec;132:104579. doi: 10.1016/j.nbd.2019.104579. Epub 2019 Aug 22.
7
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.受体配体在治疗帕金森病中作为左旋多巴的辅助手段。
Biomolecules. 2019 Apr 9;9(4):142. doi: 10.3390/biom9040142.
8
Molecular Imaging of the Cholinergic System in Parkinson's Disease.帕金森病胆碱能系统的分子影像学
Int Rev Neurobiol. 2018;141:211-250. doi: 10.1016/bs.irn.2018.07.027. Epub 2018 Sep 20.
9
PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.帕金森病中去甲肾上腺素转运体的正电子发射断层显像:聚焦扫描时间
Ann Nucl Med. 2019 Feb;33(2):69-77. doi: 10.1007/s12149-018-1305-5. Epub 2018 Oct 6.
小胶质细胞 α7 nAChR 的抗炎作用及其在神经保护中的作用。
Biochem Pharmacol. 2015 Oct 15;97(4):463-472. doi: 10.1016/j.bcp.2015.07.032. Epub 2015 Jul 29.
4
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.左旋多巴诱发异动症的突触前机制:研究结果、争议及治疗意义
Front Neurol. 2014 Dec 15;5:242. doi: 10.3389/fneur.2014.00242. eCollection 2014.
5
Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease.帕金森病早期认知正常受试者的烟碱型乙酰胆碱受体密度。
Front Aging Neurosci. 2014 Aug 14;6:213. doi: 10.3389/fnagi.2014.00213. eCollection 2014.
6
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.帕金森病左旋多巴治疗前的现代时期:来自撒哈拉以南非洲地区对运动并发症的见解。
Brain. 2014 Oct;137(Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.
7
A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia.一种用于痴呆症统计参数映射中空间归一化的标准化[18F]-氟代脱氧葡萄糖正电子发射断层显像模板。
Neuroinformatics. 2014 Oct;12(4):575-93. doi: 10.1007/s12021-014-9235-4.
8
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.纹状体多巴胺能神经元缺失预测初发帕金森病患者左旋多巴诱导的运动并发症。
Neurology. 2014 May 6;82(18):1597-604. doi: 10.1212/WNL.0000000000000385. Epub 2014 Apr 9.
9
Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease.烟碱型乙酰胆碱受体的药理学伴侣作用:帕金森病的一个治疗靶点。
Pharmacol Res. 2014 May;83:20-9. doi: 10.1016/j.phrs.2014.02.005. Epub 2014 Mar 1.
10
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.初发性帕金森病多巴胺能治疗对纹状体多巴胺周转率的影响。
Neurology. 2013 May 7;80(19):1754-61. doi: 10.1212/WNL.0b013e3182918c2d. Epub 2013 Apr 10.